ibuprofen and Disease Exacerbation studies

Research Excerpts

Excerpt	Relevance	Reference
"We compared the longterm efficacy and safety of 2 dosages of etodolac with that of ibuprofen in the treatment of active rheumatoid arthritis (RA)."	9.08	Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. ( Neustadt, DH, 1997)
"We conducted a meta-analysis of randomized controlled trials (RCTs) that compared wheezing and asthma exacerbations in children taking paracetamol versus ibuprofen."	9.05	Risk of wheezing and asthma exacerbation in children treated with paracetamol versus ibuprofen: a systematic review and meta-analysis of randomised controlled trials. ( Furuya-Kanamori, L; Nader, JD; Sherbash, M; Thalib, L, 2020)
"Ibuprofen was first advocated as a chronic therapy for cystic fibrosis lung disease in 1995, following a favorable report of a 4-year controlled trial."	8.84	Ibuprofen therapy for cystic fibrosis lung disease: revisited. ( Konstan, MW, 2008)
"Paw edema was analyzed using a plethysmometer."	5.48	Systemic treatment with resveratrol reduces the progression of experimental periodontitis and arthritis in rats. ( Casarin, RCV; Casati, MZ; Cirano, FR; Corrêa, MG; Napimoga, MH; Pimentel, SP; Pires, PR; Ribeiro, FV, 2018)
"We compared the longterm efficacy and safety of 2 dosages of etodolac with that of ibuprofen in the treatment of active rheumatoid arthritis (RA)."	5.08	Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. ( Neustadt, DH, 1997)
"We conducted a meta-analysis of randomized controlled trials (RCTs) that compared wheezing and asthma exacerbations in children taking paracetamol versus ibuprofen."	5.05	Risk of wheezing and asthma exacerbation in children treated with paracetamol versus ibuprofen: a systematic review and meta-analysis of randomised controlled trials. ( Furuya-Kanamori, L; Nader, JD; Sherbash, M; Thalib, L, 2020)
"Ibuprofen was first advocated as a chronic therapy for cystic fibrosis lung disease in 1995, following a favorable report of a 4-year controlled trial."	4.84	Ibuprofen therapy for cystic fibrosis lung disease: revisited. ( Konstan, MW, 2008)
"Ibuprofen may inhibit lung cancer progression."	2.73	Factors associated with human small aggressive non small cell lung cancer. ( Berg, CD; Church, TR; Freedman, MT; Hocking, WG; Hu, P; Kvale, PA; Oken, MM; Prorok, PC; Ragard, LR; Riley, TL; Tammemagi, CM, 2007)
"Paw edema was analyzed using a plethysmometer."	1.48	Systemic treatment with resveratrol reduces the progression of experimental periodontitis and arthritis in rats. ( Casarin, RCV; Casati, MZ; Cirano, FR; Corrêa, MG; Napimoga, MH; Pimentel, SP; Pires, PR; Ribeiro, FV, 2018)
"Ibuprofen-treated APP23 mice performed significantly better than their sham-treated counterparts and almost attained the same level of performance as control animals on a complex visual-spatial learning task."	1.36	Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. ( Coen, K; De Deyn, PP; Van Dam, D, 2010)

Research

Studies (30)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Measure of Neutrophil Migration Into the Gingival Crevices

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (16.67)	18.2507
2000's	9 (30.00)	29.6817
2010's	11 (36.67)	24.3611
2020's	5 (16.67)	2.80

Authors	Studies
de Bruin, N	1
Schneider, AK	1
Reus, P	1
Talmon, S	1
Ciesek, S	1
Bojkova, D	1
Cinatl, J	1
Lodhi, I	1
Charlesworth, B	1
Sinclair, S	1
Pennick, G	1
Laughey, WF	1
Gribbon, P	1
Kannt, A	1
Schiffmann, S	1
Fusfeld, L	1
Murphy, JT	1
Yoon, Y	1
Kam, LY	1
Peters, KE	1
Lin Tan, P	1
Shanik, M	1
Turchin, A	1
Kuhlman, G	1
Auinger, P	1
Duff-Canning, S	1
Lang, A	1
Tanner, C	1
Marras, C	1
Mortensen, R	1
Clemmensen, HS	1
Woodworth, JS	1
Therkelsen, ML	1
Mustafa, T	1
Tonby, K	1
Jenum, S	1
Agger, EM	1
Dyrhol-Riise, AM	1
Andersen, P	1
Thomas, MJ	1
Yu, D	1
Nicholls, E	1
Bierma-Zeinstra, S	1
Conaghan, PG	1
Stoner, KJ	1
Neogi, T	1
Parry, EL	1
Peat, G	1
Sherbash, M	1
Furuya-Kanamori, L	1
Nader, JD	1
Thalib, L	1
Guo, Q	1
Minnier, J	1
Burchard, J	1
Chiotti, K	1
Spellman, P	1
Schedin, P	1
Heinzl, S	1
Corrêa, MG	1
Pires, PR	1
Ribeiro, FV	1
Pimentel, SP	1
Cirano, FR	1
Napimoga, MH	1
Casati, MZ	1
Casarin, RCV	1
Sánchez-Borges, M	1
Park, HS	1
Zara, S	2
De Colli, M	1
Rapino, M	2
Pacella, S	1
Nasuti, C	2
Sozio, P	2
Di Stefano, A	2
Cataldi, A	2
Venkatesan, P	1
Konstan, MW	4
Van Dam, D	1
Coen, K	1
De Deyn, PP	1
Pasqualetti, P	1
Bonomini, C	1
Dal Forno, G	1
Paulon, L	1
Sinforiani, E	1
Marra, C	1
Zanetti, O	1
Rossini, PM	1
Scher, AI	1
Lipton, RB	1
Stewart, WF	1
Bigal, M	1
Gatson, NT	1
Travers, JB	2
Al-Hassani, M	1
Warren, SJ	1
Hyatt, AM	1
Paulus, HE	2
Di Primeo, D	2
Sharp, JT	2
Genant, HK	2
Weissman, BN	2
Weisman, MH	1
Sanda, M	2
Aizen, E	1
Kagan, G	1
Assy, B	1
Iobel, R	1
Bershadsky, Y	1
Gilhar, A	1
Reijman, M	1
Bierma-Zeinstra, SM	1
Pols, HA	1
Koes, BW	1
Stricker, BH	1
Hazes, JM	1
Chmiel, JF	1
Tammemagi, CM	1
Freedman, MT	1
Church, TR	1
Oken, MM	1
Hocking, WG	1
Kvale, PA	1
Hu, P	1
Riley, TL	1
Ragard, LR	1
Prorok, PC	1
Berg, CD	1
Colten, HR	1
Haffajee, AD	1
Dibart, S	1
Kent, RL	1
Socransky, SS	1
Davis, PB	1
Byard, PJ	1
Neustadt, DH	1
Lynch, JM	1
Schwartz, BA	1
Nistala, K	1
Murray, KJ	1

Trial	Enrollment	Study Type	Start Date	Status
Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects[NCT01315665]	15 participants (Actual)	Interventional	2011-04-30	Completed
The Role of IL-17 Neutrophils in CF Lung Inflammation[NCT02025829]	14 participants (Actual)	Observational	2014-02-28	Completed
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial[NCT00002540]	76,685 participants (Actual)	Interventional	1993-11-16	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in gingival neutrophils measured after 5 days of study treatment (consuming broccoli sprouts). Patients will perform mouthwashes with normal saline. Neutrophil counts will be performed on fresh samples. Acridine orange will be added to the saline rinses and neutrophils will be counted under the microscope. (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period

Measures of Glutathione From Blood Lymphocytes

Intervention	Neutrophils/mL (Log10) (Mean)
Healthy Volunteers	-0.06
Subjects With Cystic Fibrosis	-0.02

Change in lymphocyte glutathione measurements after 5 days of study treatment (consuming broccoli sprouts). (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period

Measures of Oxidative Stress in Urine

Intervention	Micro Molar (Mean)
Healthy Volunteers	14.3
Subjects With Cystic Fibrosis	4.7

Change in urine bromotyrosine (measured by mass spectrometry) will be measured after 5 days of study treatment (consuming broccoli sprouts). (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period

Nrf2 Activation in Nasal Epithelial Cells

Intervention	ng/mg creatinine (Log10) (Mean)
Healthy Volunteers	0.09
Subjects With Cystic Fibrosis	0.01

Number of subjects with activated Nrf-2 in the cytoplasm of nasal epithelial cells after 5 days of study treatment (consuming broccoli sprouts) (NCT01315665)
Timeframe: Baseline and of end of 5 day treatment period

Change in Sputum IL-17 Neutrophils

Intervention	participants (Number)
	Baseline	Day 5, End of treatment
Healthy Volunteers	0	4
Subjects With Cystic Fibrosis	0	4

In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards). (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation

Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, and Neutrophil Elastase

Intervention	% of neutrophils positive for IL-17 (Mean)
Begining of Exacerbation	55
End of Exacerbation	4

In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation

Death Rates From All Causes

Intervention	pg/ml (Mean)
	IL-1b (pg/ml)	IL-6 (pg/ml)	IL-8 (pg/ml)	IL-17 (pg/ml)	Neutrophil elastase activity (pg/ml)
Begining of Exacerbation	2313	53	5785	302	195
End of Exacerbation	757	37	3428	147	53

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

Deaths From All Causes

Intervention	Deaths per 10,000 PY (Number)
Control	166.6
Prostate Screening	160.5

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

Prostate Cancer Death Rates

Intervention	Participants (Number)
Control	7089
Prostate Screening	6855

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate Cancer Deaths

Intervention	Deaths per 10,000 PY (Number)
Control	3.4
Prostate Screening	3.7

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate Cancer Incidence

Intervention	Participants (Number)
Control	145
Prostate Screening	158

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate Cancer Incidence Rates

Intervention	Participants (Number)
Control	3815
Prostate Screening	4250

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Intervention	Diagnoses per 10,000 PY (Number)
Control	97.1
Prostate Screening	108.4

Number of positive screens with complications (NCT00002540)
Timeframe: One year from screening examination

T0 (Baseline) DRE Screening Results

Intervention	Positive screens w/ complications (Number)
	When DE Led to Prostate Cancer Diagnosis	When DE Did Not Lead to Prostate Cancer Diagnosis
Prostate Screening	901	124

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T0 (at study entry)

T0 (Baseline) PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	30456	2481	1192

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T0 (at study entry)

T1 DRE Screening Results

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	31507	2718	22

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T1 (one year after entry)

T1 PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	29311	2237	900

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T1 (one year after entry)

T2 DRE Screening Results

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	30159	2502	27

Digital Rectal Examination (DRE) results (NCT00002540)
Timeframe: T2 (two years after entry)

T2 PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	28391	2327	733

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T2 (two years after entry)

T3 DRE Screening Results

Intervention	Participants (Number)
	Negative	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	29063	2593	35

Digital Rectal examination (DRE) result (NCT00002540)
Timeframe: T3 (three years after entry)

T3 PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	27179	2317	748

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T3 (three years after entry)

T4 PSA Screening Result

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	27814	2676	43

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T4 (four years after entry)

T5 PSA Screening Results

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	20362	1796	12

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T5 (five years after entry)

Article	Year
Risk of wheezing and asthma exacerbation in children treated with paracetamol versus ibuprofen: a systematic review and meta-analysis of randomised controlled trials. BMC pulmonary medicine, 2020, Mar-23, Volume: 20, Issue:1 Topics: Acetaminophen; Asthma; Child; Disease Progression; Humans; Ibuprofen; Randomized Controlled Trials a	2020
Ibuprofen therapy for cystic fibrosis lung disease: revisited. Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:6 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea	2008
Ibuprofen therapy for cystic fibrosis lung disease: revisited. Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:6 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea	2008
Ibuprofen therapy for cystic fibrosis lung disease: revisited. Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:6 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea	2008
Ibuprofen therapy for cystic fibrosis lung disease: revisited. Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:6 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea	2008
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clinics in chest medicine, 2007, Volume: 28, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease	2007
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clinics in chest medicine, 2007, Volume: 28, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease	2007
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clinics in chest medicine, 2007, Volume: 28, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease	2007
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clinics in chest medicine, 2007, Volume: 28, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease	2007
Treatment of airway inflammation in cystic fibrosis. Current opinion in pulmonary medicine, 1996, Volume: 2, Issue:6 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Anti-Inf	1996

Article	Year
Short-Term Recovery Trajectories of Acute Flares in Knee Pain: A UK-Netherlands Multicenter Prospective Cohort Analysis. Arthritis care & research, 2020, Volume: 72, Issue:12 Topics: Acute Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Disease Progression; D	2020
[In process]. Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10 Topics: Acetaminophen; Asthma; Child, Preschool; Disease Progression; Fever; Humans; Ibuprofen; Pain; Prospe	2016
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging clinical and experimental research, 2009, Volume: 21, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein	2009
Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs. The Journal of rheumatology, 2004, Volume: 31, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D	2004
Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia. The Israel Medical Association journal : IMAJ, 2005, Volume: 7, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cerebral	2005
Factors associated with human small aggressive non small cell lung cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Non-Small-Cell Lung; C	2007
Clinical and microbiological changes associated with the use of 4 adjunctive systemically administered agents in the treatment of periodontal infections. Journal of clinical periodontology, 1995, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial	1995
Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatric research, 1997, Volume: 41, Issue:2 Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Disease Progression; Humans; Ibuprofen;	1997
Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. The Journal of rheumatology. Supplement, 1997, Volume: 47 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Double-B	1997
Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. The Journal of rheumatology, 2000, Volume: 27, Issue:7 Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Rel	2000

Article	Year
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. International journal of molecular sciences, 2022, Jan-19, Volume: 23, Issue:3 Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ca	2022
Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis. PloS one, 2022, Volume: 17, Issue:8 Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate;	2022
Non-steroidal anti-inflammatory drug use and markers of Parkinson's disease progression: A retrospective cohort study. Journal of the neurological sciences, 2023, Nov-15, Volume: 454 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Ibuprofen; Parkinson Disease;	2023
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Communications biology, 2019, Volume: 2 Topics: Adoptive Transfer; Aerosols; Animals; Bacterial Load; Celecoxib; Cell Differentiation; Cyclooxygenas	2019
Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI insight, 2017, 03-23, Volume: 2, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Fibroblasts; Ibuprofe	2017
Systemic treatment with resveratrol reduces the progression of experimental periodontitis and arthritis in rats. PloS one, 2018, Volume: 13, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cartilage, Articular; Dis	2018
NSAID Hypersensitivity. The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2 Topics: Allergens; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Disease Progression; Drug Hy	2019
Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model. Gerontology, 2013, Volume: 59, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Cyclic AMP Response Element-Bin	2013
Paracetamol no worse than ibuprofen in children with mild asthma. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:10 Topics: Acetaminophen; Asthma; Child; Child, Preschool; Disease Progression; Female; Humans; Ibuprofen; Male	2016
Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:3 Topics: Aging; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cognition Disorders; Dis	2010
Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia : an international journal of headache, 2010, Volume: 30, Issue:3 Topics: Adolescent; Adult; Aged; Analgesics; Aspirin; Caffeine; Chronic Disease; Disease Progression; Female	2010
Progression of toxic epidermal necrolysis after tanning bed exposure. Archives of dermatology, 2011, Volume: 147, Issue:6 Topics: Cell Line; Disease Progression; Erythema; Female; Humans; Ibuprofen; Immunoglobulins, Intravenous; K	2011
Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model. Brain research, 2011, Sep-15, Volume: 1412 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cyclooxygenase Inhibitors; Disea	2011
Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis and rheumatism, 2005, Volume: 52, Issue:10 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Disease Progression; Female; Follow-Up St	2005
Airway inflammation in cystic fibrosis. The New England journal of medicine, 1995, Mar-30, Volume: 332, Issue:13 Topics: Adult; Child, Preschool; Cystic Fibrosis; Disease Progression; Humans; Ibuprofen; Pneumonia	1995
Co-existent sickle cell disease and juvenile rheumatoid arthritis. Two cases with delayed diagnosis and severe destructive arthropathy. The Journal of rheumatology, 2001, Volume: 28, Issue:9 Topics: Adolescent; Anemia, Sickle Cell; Arthritis, Juvenile; Disease Progression; Drug Therapy, Combination	2001

ibuprofen and Disease Exacerbation